TriSalus Life Sciences, Inc. TLSI
- Market cap
- $303.6M
- P/E
- 0.0×
Follow TLSI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 9.45 | 8.99 | 3.32 | 3.50 | 3.42 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 11.18 | 10.68 | 16.24 | 10.42 | 7.95 |
High Price
|
|||
| — | — | — | — | — | — | 3 | 112 | 110 | 102 |
Employees
|
|||
| — | — | — | — | — | — | 4 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | 12 | 19 | 29 | 45 |
Revenue
|
|||
| — | — | — | — | — | — | 81.79% | 85.93% | 86.06% | 84.57% |
Gross Margin
|
|||
| — | — | — | — | (1) | 5 | (47) | (59) | (30) | (39) |
EBT
|
|||
| — | — | — | — | 0.00% | 0.00% | (380.53%) | (320.64%) | (102.07%) | (86.86%) |
EBT Margin
|
|||
| — | 0 | — | — | (1) | 5 | (47) | (59) | (30) | (39) |
Net Income
|
|||
| — | — | — | — | — | — | 0 | 1 | 1 | 2 |
Depreciation
|
|||
| — | — | — | — | 0.00 | 0.00 | 39.99 | 1.97 | 1.16 | 1.19 |
Revenue/Sh
|
|||
| — | — | — | — | (0.11) | 0.76 | (152.22) | (6.73) | (1.31) | (1.84) |
Earnings/Sh
|
|||
| — | — | — | — | (0.11) | (0.28) | (104.24) | (5.38) | (1.61) | (0.48) |
Cash Flow/Sh
|
|||
| — | — | — | — | 0.00 | 0.00 | (2.54) | (0.12) | (0.01) | (0.02) |
Capex/Sh
|
|||
| — | — | — | — | (0.11) | (0.28) | (106.77) | (5.50) | (1.63) | (0.50) |
Free CF/Sh
|
|||
| — | — | — | — | (3.40) | (2.67) | (568.81) | (2.88) | (1.02) | (0.89) |
Book Value/Sh
|
|||
| — | — | — | — | 6 | 6 | 0 | 9 | 25 | 38 |
Shares
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | 0.00 | 4.19 | 4.31 | 5.86 |
PS Ratio
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | 0.00 | 3.64 | 4.78 | 6.14 |
EV/Sales
|
|||
| — | — | — | — | — | — | 0.12 | (1.30) | (3.36) | (14.16) |
EV/FCF
|
|||
| — | — | — | — | (1) | (2) | (32) | (51) | (41) | (18) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | (1) | (1) | 0 | (1) |
Capex
|
|||
| — | — | — | — | (1) | (2) | (33) | (52) | (41) | (19) |
FCF
|
|||
| — | — | — | — | 2 | (1) | (15) | 6 | 10 | 21 |
Working Cap'
|
|||
| — | — | — | — | — | 1 | 1 | — | 22 | 33 |
Total Debt
|
|||
| — | — | — | — | (1) | 0 | (8) | (12) | 14 | 13 |
Net Debt
|
|||
| — | — | — | — | (21) | (17) | (176) | (27) | (26) | (34) |
Sh' Equity
|
|||
| — | — | — | — | (0.56%) | 1.90% | (36.71%) | (273.01%) | (136.85%) | (235.03%) |
ROA
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | (0.60%) | (24.96%) | 51.82% | 62.54% | 125.50% | 233.25% |
ROE
|
|||
TriSalus Life Sciences, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TMCI Treace Medical Concepts, Inc. | $295.3M | 0.0× | Compare |
| LAB Standard BioTools Inc. | $291.7M | 3.4× | Compare |
| RCEL Avita Medical Inc. | $289.1M | 0.0× | Compare |
| CATX Perspective Therapeutics, Inc. | $285.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CV CapsoVision, Inc. | $328.3M | 2.1× | Compare |
| VMD Viemed Healthcare, Inc. | $335.9M | 23.4× | Compare |
| SI Shoulder Innovations, Inc. | $354.1M | 0.0× | Compare |
| INFU InfuSystems Holdings, Inc. | $252.8M | 30.3× | Compare |
TriSalus Life Sciences, Inc. (TLSI) key facts
- TriSalus Life Sciences, Inc. (TLSI) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024.
- As of September 25, 2026, TLSI traded at $4.34, a market capitalization of $303.6 million.
- Return on equity was 233.3% and debt-to-equity 5.05.
TriSalus Life Sciences, Inc. (TLSI) Latest News
23 Sep
TriSalus Life Sciences (TLSI) surges 15.6% in pre-market trading after the FDA granted 510(k) clearance for TriNav Advance, a device in the Pressure-Enabled Drug Delivery portfolio for liver embolization. The device targets smaller distal vessels with a compatible microcatheter and can operate in two configurations: a telescoping mode for distal vessels or a high-flow mode that infuses through a larger lumen without another microcatheter. CEO Mary Szela says the clearance enhances the company's liver-embolization portfolio, while CMO Richard Marshall notes potential use in tortuous anatomies. A limited market release is planned in coming weeks. TriSalus has also raised its 2026 revenue guidance previously; broader indices showed little movement at the time of the report. FDA clearance for a new TriNav Advance device expands the product portfolio and could meaningfully influence adoption, revenue, and investor sentiment.
22 Sep
TriSalus Life Sciences has received FDA 510(k) clearance for TriNav Advance, the latest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio. TriNav Advance provides access to small, distal vessels via a compatible microcatheter while preserving PEDD’s enhanced therapeutic delivery and off-target protection. Interventional radiologists can pair it with their preferred microcatheter, expanding applicability across liver-directed therapies and potentially other embolization procedures. The company plans a limited market release in the coming weeks. TriNav Advance can be used in two configurations: Telescoping—proximally positioned SmartValve with a microcatheter for selective delivery to distal vessels; and High-flow—infusion through a large lumen without a microcatheter. Executives CEO Mary Szela and CMO Richard Marshall say the device broadens the toolset for challenging anatomies, potentially accelerating PEDD adoption. Regulatory clearance broadens the PEDD portfolio and expands addressable embolization procedures, potentially boosting adoption and future revenue.
18 Aug
TriSalus Life Sciences expands tumor-treatment options and flags an FDA catalyst at a growth conference. Tumor-treatment expansion plus FDA catalyst at conference points to major regulatory and commercial upside for TLSI.
7 Aug
TriSalus Life Sciences secured a new CMS G-code expanding reimbursement access for its drug delivery systems, reported in Q2 2026 earnings call highlights. New CMS G-code directly improves reimbursement and accelerates commercial uptake of TriSalus products.
TriSalus Life Sciences reported Q2 earnings call highlights covering financial results, operational updates and strategic outlook for the company. Q2 earnings highlights typically influence short-term investor views on financial performance without indicating major strategic shifts.
6 Aug
TriSalus Life Sciences reported its second quarter 2026 financial results. Quarterly earnings updates provide financial performance data that can shift near-term investor views without guaranteeing major strategic changes.
13 May
TriSalus Life Sciences Inc (TLSI) Q1 2026 earnings call highlights strategic expansion efforts alongside key financial and operational updates. Strategic expansions in Q1 2026 earnings call signal major moves likely to enhance TLSI's competitive positioning and investor sentiment.
12 May
TriSalus Life Sciences (TLSI) released Q1 earnings call highlights, covering financial results, operational updates, and forward guidance. Q1 earnings call highlights detail financial performance and strategic initiatives with potential to significantly shape TLSI's market trajectory.
TriSalus Life Sciences, Inc. released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q1 2026 earnings summary discloses financial performance and strategic outlook, likely driving significant shifts in investor sentiment and company trajectory.
TriSalus Life Sciences reported first quarter 2026 results showing commercial and clinical progress to drive long-term growth. Q1 2026 results reveal commercial and clinical advancements that boost financial performance and strategic positioning.
TriSalus Life Sciences' real-world PEDD study, published in the Journal of Comparative Effectiveness Research, demonstrates improved clinical outcomes and meaningful charge avoidance. Peer-reviewed real-world data validating PEDD technology's efficacy and cost savings boosts TriSalus' market credibility and adoption potential.
TriSalus Life Sciences, Inc. (TLSI) reported a Q1 loss and revenue below analyst estimates. Q1 loss and revenue shortfall indicate weaker financial performance, moderately affecting investor sentiment and short-term market trajectory.
10 May
TriSalus Life Sciences, Inc. (TLSI) initiates patient enrollment for the PREDICTT Liver Tumor Clinical Trial, advancing its Pressure-Enabled Drug Delivery platform for hepatocellular carcinoma and metastatic liver tumors. Initiating PREDICTT trial enrollment advances TLSI's oncology pipeline milestone, signaling progress toward potential regulatory approval and positive market sentiment.
4 May
TriSalus Life Sciences, Inc. (TLSI) announces launch of PREDICTT clinical trial evaluating Pressure-Enabled Drug Delivery (PEDD) system—via TriNav® Infusion System—for liver tumors, aiming to assess delivery efficiency, tumor response, and safety in up to 30 patients across U.S. sites. PREDICTT trial launch represents major advancement of TLSI's core PEDD technology into high-value liver cancer market, potentially boosting clinical validation and investor confidence.
7 Apr
TriSalus Life Sciences, Inc. (TLSI) appoints Richard Marshall, M.D., as Chief Medical Officer to lead clinical development and regulatory strategy. Appointing a new Chief Medical Officer enhances clinical leadership and pipeline advancement but does not fundamentally transform the company's trajectory.
18 Mar
TriSalus Life Sciences announces publication demonstrating enhanced delivery and immune activation of nelitolimod using Pressure-Enabled Drug Delivery in liver tumor models. Preclinical data validating enhanced nelitolimod delivery and immune activation via PEDD in liver tumors supports TLSI's oncology platform and could moderately boost investor sentiment.
12 Mar
Canaccord Genuity lowered its price target for TriSalus Life Sciences (TLSI) to $7 from $12 while maintaining a Buy rating. Lowered price target reflects moderated growth expectations, likely influencing investor sentiment and short-term stock performance without altering long-term trajectory.
6 Mar
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 earnings call summary highlights financial results, operational updates, and forward-looking guidance for the oncology immunotherapy company. Q4 earnings summaries provide critical revenue figures, pipeline progress, and outlook that drive substantial shifts in investor confidence and stock trajectory.
TriSalus Life Sciences released Q4 earnings call highlights, covering financial results, operational updates, and forward guidance. Q4 earnings highlights detail financial performance and strategic outlook, significantly influencing TLSI's trajectory and investor sentiment.
TriSalus Life Sciences Inc (TLSI) reported strong revenue growth in Q4 2025 earnings call, alongside key operational advancements and positive outlook. Strong Q4 2025 revenue growth indicates significant positive shift in TLSI's financial trajectory and investor sentiment.
5 Mar
TriSalus Life Sciences (TLSI) released Q4 2025 earnings call transcript detailing financial results, revenue growth, pipeline updates, and forward guidance. Q4 earnings transcript discloses key financial metrics, operational progress, and strategic outlook that significantly shape investor expectations and market trajectory.
TriSalus Life Sciences reported fourth quarter and year-end 2025 financial results and reaffirmed its 2026 revenue guidance. Reporting annual results and reaffirming next-year revenue guidance significantly shapes investor sentiment and financial trajectory.
20 Feb
TriSalus Life Sciences, Inc. (TLSI) announced the pricing of a $40.0 million public offering of common stock. A $40 million public offering provides substantial capital infusion to advance clinical programs and operations, significantly bolstering financial position and growth prospects.
19 Feb
TriSalus Life Sciences, Inc. (TLSI) announced a proposed public offering of its common stock to raise capital for general corporate purposes. Proposing a public offering enables substantial capital raising for growth but introduces shareholder dilution, significantly impacting TLSI's financial trajectory and market valuation.
9 Feb
TriSalus Life Sciences, Inc. has appointed Michael Stansky, a seasoned healthcare investor, to its Board of Directors. Stansky brings extensive experience in the healthcare sector, having held various leadership roles and contributed to numerous successful investments. His appointment is expected to enhance the company's strategic direction and governance as it continues to focus on innovative therapies for cancer treatment. The addition of a veteran investor to the board may positively influence strategic decisions and investor confidence, but the overall impact on the company's trajectory remains limited.
14 Jan
TriSalus Life Sciences, Inc. (TLSI) has been upgraded to a 'Buy' rating by analysts, reflecting positive sentiment regarding the company's growth potential and strategic initiatives. This upgrade is based on recent developments in their product pipeline and market positioning, suggesting that TLSI is well-positioned for future success in the biopharmaceutical sector. The upgrade indicates significant confidence in TLSI's strategic direction and potential market impact.
12 Jan
TriSalus Life Sciences, Inc. (TLSI) announced its preliminary financial results for the fourth quarter and full year of 2025, highlighting significant revenue growth and providing guidance for 2026. The company reported an increase in product sales and expanded its market presence, indicating a positive trajectory for future performance. TLSI's strategic initiatives and product pipeline are expected to contribute to continued revenue growth in the upcoming year. The announcement of revenue growth and guidance for 2026 suggests significant strategic moves that could alter the company's trajectory.
10 Dec
TriSalus Life Sciences, Inc. (TLSI) is highlighted among three growth companies with high insider ownership, achieving a notable 29% revenue growth. The article emphasizes the significance of insider ownership as a positive indicator of company performance and investor confidence. TLSI's growth trajectory is positioned favorably within the competitive landscape, suggesting potential for continued success. The significant revenue growth and high insider ownership indicate strong investor confidence and potential for future strategic moves.
4 Dec
TriSalus Life Sciences, Inc. will host a virtual Key Opinion Leader (KOL) event on December 15, 2025, to discuss the TriNav Infusion System, which is designed for the treatment of symptomatic thyroid disease. This event aims to provide insights into the system's capabilities and its potential impact on patient care. The event may enhance product awareness and influence market sentiment, but its overall effect on the company's trajectory is expected to be limited.
18 Nov
TriSalus Life Sciences, Inc. has launched the TriNav® XP Infusion System, enhancing its Pressure-Enabled Drug Delivery™ technology. This new system aims to improve treatment options for patients with solid tumors by enabling more effective drug delivery directly to the tumor site. The TriNav® XP is designed to optimize the infusion process, potentially leading to better patient outcomes and expanding the company's market presence in oncology. The launch of the TriNav® XP Infusion System represents a significant advancement in drug delivery technology that could enhance treatment efficacy and market positioning.